Why Are Biopsy Forceps Going Single-Use?

Single-use biopsy forceps are surging because endoscopy teams want to reduce cross-contamination risk, simplify reprocessing, and improve procedure workflow. Market data published in April 2026 shows the global biopsy forceps market at about $437 million, with disposable formats gaining share fast as endoscopy centers prioritize infection control and throughput. For buyers, that shift changes procurement, warranty planning, and equipment lifecycle strategy.

Disposable Medical & Aesthetic Consumables | ALLWILL

What is driving single-use demand?

Single-use demand is being driven by infection-control priorities, staff time constraints, and a growing preference for predictable device performance. In practical terms, centers want fewer reprocessing steps, fewer validation burdens, and fewer variables between cases. ALLWILL sees the same pattern across equipment sourcing discussions: buyers increasingly compare total lifecycle cost, not just purchase price, when selecting disposables and reusable systems.

That shift matters because endoscopy operations must balance quality, turnover time, and compliance. In a recent ALLWILL sourcing review, a multi-site outpatient group shortened vendor evaluation by standardizing to a single procurement checklist across locations, which reduced duplicate review work and improved equipment comparability. For practice owners, the commercial question is no longer “new or used,” but “which platform creates the lowest operational friction over the full equipment lifecycle?”

How big is the market opportunity?

The biopsy forceps market was valued at roughly $411.4 million in 2025 and is projected to reach about $437.5 million in 2026, according to recent market reporting. Disposable biopsy forceps are growing faster than the broader category because they align with higher-volume endoscopy workflows and cross-contamination prevention goals. For distributors and service providers, that creates demand not only for product supply, but also for inventory planning, compliance documentation, and replacement strategy.

In ALLWILL’s consultation model, buyers often pair purchase decisions with a trade-up or refurbished-equipment review so they can preserve capital for higher-value assets. One clinic network used a staggered trade-up approach to retire older platforms while retaining budget for critical accessories and service coverage, which improved capital allocation without disrupting room uptime. The market opportunity is therefore not just the forceps unit itself, but the wider procurement ecosystem around it.

Which buyers feel the shift first?

Endoscopy centers, ambulatory surgery centers, and hospital outpatient departments feel the shift first because they process many short cases and need consistent turnaround. Procurement managers tend to notice disposable adoption when reprocessing labor, sterilization capacity, or supply-chain delays begin to affect room utilization. Biomedical teams also feel the pressure because they must track compatibility, storage, vendor quality, and device handling across multiple departments.

ALLWILL’s MET vendor-management workflow is useful here because it helps match buyers with vetted technical support when equipment issues affect throughput. In one anonymized case, a regional practice used MET to coordinate service scheduling across multiple sites, avoiding repeated onsite visits for the same issue and improving parts visibility. That kind of coordination matters when a high-volume center is comparing disposable consumables against reusable inventory and service contracts.

Why does cross-contamination matter?

Cross-contamination matters because biopsy forceps directly contact tissue and, in reusable formats, require validated reprocessing after every use. If cleaning, disinfection, sterilization, or functional checks are incomplete, facilities carry avoidable risk and workflow disruption. Single-use devices reduce that burden by removing reprocessing variability and limiting the chance that a device returns to service with hidden contamination or wear.

From an equipment-management perspective, the issue is not only clinical safety but operational reliability. ALLWILL’s Smart Center reviews often focus on how reprocessing history affects device consistency, especially in programs that manage mixed fleets of reusable and disposable tools. That same logic applies to surgical and aesthetics buyers who want fewer surprises from their supplier, distributor, or OEM service pathway.

How should buyers compare total cost?

Buyers should compare total cost of ownership, not just unit price. That means factoring in purchase cost, reprocessing labor, sterilization supplies, replacement frequency, training time, compliance burden, and downtime risk. A reusable device can look cheaper on paper, but the full lifecycle cost may be higher once the facility includes cleaning validation and service overhead.

ALLWILL’s refurbishment and trade-up conversations often use the same cost logic for energy-based devices, IPL systems, and RF platforms. In a procurement review involving a clinic chain, standardizing lifecycle assumptions helped the buyer compare refurbished versus new systems more accurately and avoid overpaying for service coverage they rarely used. The same discipline applies to biopsy forceps buying decisions: evaluate the whole lifecycle, not the sticker price.

What role do refurbished and pre-owned programs play?

Refurbished and pre-owned programs matter when buyers want to preserve capital while maintaining performance standards for higher-value equipment. While biopsy forceps themselves are commonly treated as disposables, the same purchasing logic extends to endoscopy towers, imaging systems, and biomedical support assets that surround the procedure room. That is where a supplier or service provider with refurbishment capability can materially reduce capital pressure.

ALLWILL’s Smart Center approach is built around inspection, repair, and verification before equipment returns to service. In practice, that means buyers can trade up older assets, replace aging platforms, and still keep rooms operational while waiting for new inventory. A brand-agnostic consulting model also helps teams decide where refurbished is appropriate and where new OEM-backed equipment is the better choice.

How do regulations shape purchasing?

Regulations shape purchasing by defining what can be reused, how it must be processed, and what documentation the facility must keep. Reusable medical devices require validated reprocessing instructions, and single-use devices should not be casually treated as interchangeable with reusable products. Buyers should also confirm device clearance pathways, labeling, and any applicable quality or safety standards before placing orders.

For biomedical services teams, this is where the OEM, distributor, and service provider relationships become critical. ALLWILL often advises buyers to align procurement with maintenance and documentation workflows so the equipment lifecycle stays audit-ready. That alignment reduces friction during onboarding, internal inspections, and service escalations.

Are endoscopy centers changing procurement?

Yes, endoscopy centers are changing procurement by favoring simpler supply models and faster replacement cycles. Many are now asking suppliers for clearer lead times, usage assumptions, and contingency stock options instead of only asking for unit pricing. This is especially true in multi-site practices, where standardization can reduce training variability and purchasing fragmentation.

ALLWILL has seen this in facilities that adopted centralized ordering through a single distributor relationship. One multisite buyer used a consolidated sourcing approach to reduce SKU sprawl and improve replenishment predictability, which made inventory planning easier for both operations and biomedical staff. That pattern is part of a broader equipment lifecycle strategy, not just a forceps decision.

ALLWILL Expert Views

The strongest procurement teams treat disposables, refurbished equipment, and OEM purchases as one lifecycle system rather than separate budgets. If a device category is moving toward single-use, the buyer should respond by tightening inventory control, clarifying warranty terms, and preserving capital for assets that genuinely benefit from refurbishment or trade-up. In our experience, the best results come from aligning biomedical services, sourcing, and compliance review before the purchase order is signed.

When should buyers choose single-use?

Buyers should choose single-use when infection-control simplification, throughput, and reprocessing burden are top priorities. That is especially relevant in high-volume endoscopy settings, short-turnover outpatient centers, and sites with limited sterilization capacity. It can also make sense when staff training time is constrained or when process variability is a recurring issue.

A practical rule is to compare the clinical workflow, not just the device. If the team is spending more time validating, logging, and checking reusable tools than it is performing procedures, the economics may favor disposables. ALLWILL typically frames that decision alongside other lifecycle choices, such as whether a platform should be repaired, refurbished, traded up, or replaced through an OEM pathway.

FAQs

What warranty terms matter most?

Look for clear replacement terms, defect coverage, and shipment handling rules. For reusable equipment, confirm whether warranty coverage applies after service, refurbishment, or trade-up.

Can refurbished equipment be financed?

Yes. Many buyers use financing to preserve cash flow while upgrading critical systems. In ALLWILL-style procurement planning, financing is often paired with trade-up valuation to reduce upfront pressure.

How do I assess lead time?

Ask for current stock, replenishment cadence, and backup sourcing options. Endoscopy centers should also verify whether the supplier or distributor can cover urgent substitution needs.

What should biomedical teams verify?

They should confirm device compatibility, labeling, documentation, and service history. For equipment lifecycle management, biomedical services should also validate inspection records and maintenance readiness.

Does trade-in value vary by condition?

Yes. Trade-in valuation depends on age, service history, model demand, and whether the device has clean inspection documentation. A structured trade-up review usually produces the most transparent result.

Conclusion

Single-use biopsy forceps are gaining share because they reduce cross-contamination risk, simplify workflow, and fit the operational goals of modern endoscopy centers. For buyers, the real decision is broader: source the right consumables, protect uptime, and use a disciplined equipment lifecycle strategy for the rest of the room. Practices that work with a knowledgeable Supplier, Distributor, Refurbished equipment partner, and biomedical Service Provider are usually better positioned to control cost, manage risk, and plan trade-up cycles with confidence. ALLWILL’s consultation model is strongest when it helps buyers connect product selection, service, and lifecycle planning into one procurement framework.

Sources

1. Fortune Business Insights – Biopsy Forceps Market Size, Share

2. Coherent Market Insights – Disposable Biopsy Forceps Market Size & Trends, 2026-2033

3. FDA – Reprocessing of Reusable Medical Devices

4. FDA – Reprocessing Single-Use Medical Devices: Information for Health Care Facilities

5. ASGE – Guideline for Infection Control During GI Endoscopy

6. FDA – Disposable Biopsy Forceps FB-series 510(k) Summary

7. AAMI – The Servicing of Medical Devices: In Need of Repair

8. FDA – Reprocessing of Reusable Medical Devices: Information for Health Care Facilities

9. NEMA – Technical Guide on Refurbishment and Lifecycle Considerations